CYRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Cryoport, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$16.98+0.14 (+0.83%)
Close on Oct 19, 2026
- Market cap
- $856.52M
- P/E (TTM)
- –
- Dividend yield
- –
Cryoport, Inc. revenue by segment
By business segment
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Life Sciences Services | $107.65M | $105.25M | $101.03M | $97.12M | $92.93M | – | $85.34M | – | – | – | – | – | 57.7% | +15.8% |
| Life Sciences Products | $78.81M | $77.69M | $75.15M | $75.06M | $73.34M | – | $71.43M | – | – | – | – | – | 42.3% | +7.5% |
| Aggregate of reportable segment | – | – | $176.18M | $172.56M | $166.59M | $160.66M | $156.77M | – | – | – | – | – | – | – |
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Service | $104.13M | $100.53M | $96.50M | $92.97M | $89.64M | $85.42M | $82.04M | $97.59M | $112.68M | $127.74M | $79.49M | $140.15M | 55.8% | +16.2% |
| BioLogistics Solutions | $83.76M | $81.28M | $78.14M | $75.31M | $72.84M | $69.59M | $67.02M | $82.95M | $98.48M | $113.85M | $65.91M | – | 44.9% | +15.0% |
| Product | $82.32M | $82.41M | $79.68M | $79.21M | $76.62M | $75.09M | $74.73M | $74.98M | $77.73M | $79.99M | $89.17M | $96.20M | 44.2% | +7.4% |
| BioStorage/BioServices | $20.37M | $19.26M | $18.36M | $17.66M | $16.80M | $15.83M | $15.03M | $14.65M | $14.21M | $13.89M | $13.59M | – | 10.9% | +21.2% |
| Biopharmaceutical | – | – | – | – | – | – | – | – | – | – | $192.58M | $195.20M | – | – |
| Animal Health | – | – | – | – | – | – | – | – | – | – | $30.38M | $31.10M | – | – |
| Reproductive Medicine | – | – | – | – | – | – | – | – | – | – | $10.29M | $10.05M | – | – |
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Americas | $137.68M | $134.02M | $131.26M | $128.17M | $122.87M | $119.05M | $113.55M | $105.49M | $109.22M | $110.97M | $117.90M | $127.58M | 73.8% | +12.1% |
| Europe, the Middle East, and Africa (EMEA) | $30.70M | $28.51M | $25.13M | $24.93M | $24.50M | $25.20M | $27.02M | $33.51M | $41.55M | $50.12M | $27.65M | $65.38M | 16.5% | +25.3% |
| Asia Pacific (APAC) | $18.07M | $20.41M | $19.78M | $19.08M | $18.89M | $16.27M | $16.20M | $24.25M | $30.33M | $37.32M | $23.12M | $43.40M | 9.7% | -4.4% |
From the segment and revenue-disaggregation notes of Cryoport's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.